Commonwealth Equity Services
PHAT icon

Commonwealth Equity Services’s Phathom Pharmaceuticals PHAT Stock Holding History

Commonwealth Equity Services’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$358K Buy
32,230
+1,290
+4% +$16.3K ﹤0.01% 3518
2025
Q4 		$513K Buy
30,940
+324
+1% +$4.63K ﹤0.01% 3163
2025
Q3 		$360K Sell
30,616
-940
-3% -$9.7K ﹤0.01% 3481
2025
Q2 		$303K Sell
31,556
-20,875
-40% -$116K ﹤0.01% 3568
2025
Q1 		$329K Buy
52,431
+1,659
+3% +$10.1K ﹤0.01% 3417
2024
Q4 		$412K Buy
50,772
+40,362
+388% +$500K ﹤0.01% 3134
2024
Q3 		$188K Sell
10,410
-1,186
-10% -$16.6K ﹤0.01% 3729
2024
Q2 		$119K Buy
+11,596
New +$119K ﹤0.01% 3779

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return